This project was completed by Intensity. Intensity joined Secretariat on February 1, 2023.
Intensity determined the extent to which certain patents in the field of molecular diagnostics were unenforceable due to prosecution laches. Intensity also performed an analysis of damages relating to alleged infringement of patented technology by quantifying reasonable royalties.
Intensity was retained to analyze the ongoing investments, marketing, and research in a biotechnology company specializing in molecular diagnostics. Intensity assessed the extent to which these were or were not sunk costs and the extent to which these costs precluded alternative research and investment spending. Intensity then determined a reasonable and market-based royalty for technology as part of molecular diagnostics testing kits, based on consideration of the market for these kits, the licensing policies and histories of both companies, product sales and profitability.
Intensity also performed an analysis of damages relating to alleged infringement of patented technology by quantifying reasonable royalties based on consideration of relevant licensing agreements, accused sales and profitability, and the unique contribution of the patented technology.
Economic issues include apportionment, licensing, and reasonable royalties.
Statistics Tools Chart A Path For AI Use In Expert Testimony
As AI and machine learning tools become more common in expert workflows, courts are increasingly scrutinizing their use under Federal Rule of Evidence 702. In The Risks and a Path Forward for AI and Machine Learning Tools in Expert Testimony, we examine recent cases where AI-assisted opinions were excluded due to concerns about reliability, transparency, and expert understanding.
In this GIR article, Stephen Millington and Dominique Dondelinger examine the growing fraud risks facing the Gulf region amid rapid economic expansion and transformative Vision 2030 strategies.
Public Cos. Must Heed Disclosure Risks Amid Trade Chaos
Ongoing uncertainties caused by the trade war and President Donald Trump’s evolving stance on tariffs and trade restrictions, including sanctions and export controls, have exponentially escalated financial reporting pressures on public companies. In this article, we discuss the key financial reporting and disclosure risks, as well as takeaways, for public companies as they navigate significant market instability in international trade.